Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2015.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January through February 2014.

G protein-coupled receptors are the most prolific initiators of cell signaling pathways. The largest class of drug targets, they are also, unfortunately, the most intractable to drug development. Three research papers shows how combining different techniques -- crystallography, hydrogen exchange, and electron microscopy -- can shed new light on the nuances of GPCR signaling and how this kind of integrated approach could help identify new drug targets.

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.